NCT03459859View on ClinicalTrials.gov

Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

June 25, 2021

Study Completion Date

June 25, 2021

Conditions
Acute Myelogenous LeukemiaAMLAdvanced Myelodysplastic SyndromesMDS
Interventions
DRUG

Pevonedistat

Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.

DRUG

Cytarabine

Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.

Trial Locations (1)

33136

University of Miami, Miami

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Justin Watts, MD

OTHER